Overview

Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of MP-513 in combination with Metformin in patients with type 2 diabetes for 24 weeks administration and to evaluate the safety and efficacy of MP-513 in combination with Metformin with an extension treatment for up to 52 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation
Treatments:
Metformin